Boehringer Ingelheim Enters Cancer Vaccine Field with CureVac Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 10 (Table of Contents)
Published: 15 Oct-2014
DOI: 10.3833/pdr.v2014.i10.2068 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Despite a number of high profile setbacks in the development of lung cancer vaccines, Boehringer Ingelheim has paid German biotech CureVac €35 M (US$45 M) upfront for exclusive global rights to develop and commercialise its clinical-stage therapeutic mRNA vaccine CV9202, which it plans to investigate in combination with Gilotrif® (afatinib) and chemoradiation in patients with non-small-cell lung cancer (NSCLC)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS